Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 15/20 | 0.79 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4484982 | 0.89 | HCRTR1 (0.81) | HCRTR1HCRTR2HDAC6CFD | |
| SCHEMBL4483151 | 0.89 | HCRTR1 (1.00) | HCRTR1HCRTR2HDAC6 | |
| SCHEMBL4487918 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2HDAC6TSHR | |
| SCHEMBL4479289 | 0.85 | HCRTR1 (0.73) | HCRTR1HCRTR2GAAHDAC6TSHR | |
| SCHEMBL8250432 | 0.85 | HCRTR1 (0.70) | HCRTR1HCRTR2GAAMAPTHDAC6 | |
| SCHEMBL4474746 | 0.85 | HCRTR1 (0.70) | HCRTR1HCRTR2HDAC6TSHRKMT2A | |
| SCHEMBL4474741 | 0.85 | HCRTR1 (0.70) | HCRTR1HCRTR2HDAC6TSHRKMT2A | |
| SCHEMBL4482543 | 0.85 | HCRTR1 (0.75) | HCRTR1HCRTR2HDAC6KMT2A | |
| SCHEMBL4492861 | 0.83 | HCRTR1 (0.70) | HCRTR1HCRTR2HDAC6TSHR | |
| SCHEMBL4474283 | 0.83 | HCRTR1 (0.67) | HCRTR1HCRTR2LMNAHDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| EP-1888563-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127550-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | HCRTR1, HCRTR2, NPSR1 | HCRTR1 1/4885HCRTR2 2/4885LMNA 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.